Apellis Pharmaceuticals’ (APLS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report released on Monday morning,Benzinga reports. The firm currently has a $57.00 target price on the stock. HC Wainwright also issued estimates for Apellis Pharmaceuticals’ Q1 2025 earnings at ($0.47) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.42) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at $0.95 EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $3.84 EPS.

APLS has been the topic of a number of other research reports. Robert W. Baird lowered their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. Bank of America lowered their target price on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Scotiabank reduced their price objective on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reduced their price objective on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.53.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $26.00 on Monday. The firm’s 50-day moving average price is $29.53 and its 200-day moving average price is $31.30. Apellis Pharmaceuticals has a 1-year low of $23.77 and a 1-year high of $64.33. The firm has a market capitalization of $3.23 billion, a P/E ratio of -12.81 and a beta of 0.93. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $212.50 million for the quarter, compared to analyst estimates of $197.92 million. During the same quarter in the prior year, the business posted ($0.73) EPS. The firm’s revenue was up 45.2% compared to the same quarter last year. Equities research analysts anticipate that Apellis Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel David O. Watson sold 4,965 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $28.70, for a total value of $142,495.50. Following the completion of the transaction, the general counsel now directly owns 107,756 shares of the company’s stock, valued at approximately $3,092,597.20. This trade represents a 4.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Caroline Baumal sold 2,816 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the sale, the insider now owns 55,560 shares in the company, valued at $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 60,365 shares of company stock valued at $1,810,479. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. KBC Group NV lifted its stake in Apellis Pharmaceuticals by 34.8% in the 3rd quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after purchasing an additional 679 shares in the last quarter. Xponance Inc. lifted its stake in Apellis Pharmaceuticals by 5.6% in the 4th quarter. Xponance Inc. now owns 14,072 shares of the company’s stock worth $449,000 after purchasing an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Apellis Pharmaceuticals by 2,707.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock worth $25,000 after purchasing an additional 758 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after purchasing an additional 781 shares in the last quarter. Finally, Woodline Partners LP lifted its stake in Apellis Pharmaceuticals by 0.5% in the 4th quarter. Woodline Partners LP now owns 189,477 shares of the company’s stock worth $6,046,000 after purchasing an additional 913 shares in the last quarter. 96.29% of the stock is currently owned by hedge funds and other institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).